AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Nano Biomedicine and Engineering Article
PDF (1.7 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

New Developments of Gastric Cancer Biomarker Research

Hualin Fu1,2( )
Institute of Nano Biomedicine and Engineering, Key Laboratory for Thin Film and Microfabrication of the Ministry of Education, Department of Instrument Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, 200240, China
National Center for Translational Medicine, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, 200240, China
Show Author Information

Abstract

Gastric cancer is a deadly disease with high incidence and mortality rate in China. Early detection and treatment of gastric cancer showed significantly better 5-year survival rate. Conventional screening methods of gastric cancer include barium meal or endoscopic screening. There is a great need to find new biomarkers of gastric cancer for simpler, faster, and non-invasive screening of gastric cancer. A large array of molecules such as protein markers, metabolite markers, RNA markers, breath organic molecules have been identified as potential markers of gastric screening. Among them, pepsinogens and gastrin-17 have been applied in large scale of population screening. New species of metabolite markers, microRNA markers and breath molecules may further enhance the simplicity, sensitivity and specificity of gastric cancer screening.

Keywords

Volatile organic compoundBiomarkerProteinRNAGastric cancerMetabolite

References

[1]

R. Zheng, S. Zhang, and L. Wu, Report of Incidence and Mortality from China Cancer Registries in 2008. China Cancer, 2012, 21(1): 1-12.
Google Scholar
[2]
N. Howlader, A.M. Noone, M. Krapcho, et al. (eds), SEER cancer statistics review, 1975-2011. National Cancer Institute. Bethesda, 2014.
[3]

J.M. Kang, N. Kim, J.Y. Yoo, et al., The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea. Helicobacter, 2008, 13(2): 146-156.
Crossref Google Scholar
[4]

N. Kim, H.C. Jung, The role of serum pepsinogen in the detection of gastric cancer. Gut Liver, 2010, 4(3): 307-319.
Crossref Google Scholar
[5]

J.S. Edkins, The chemical mechanism of gastric secretion. J Physiol, 1906, 34(1-2): 133-144.
Crossref Google Scholar
[6]

R. Kikuchi, Y. Abe, K. Iijima, et al., et al., Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with high-risk of early gastric cancer. Tohoku J Exp Med, 2011, 223(1): 35-44.
Crossref Google Scholar
[7]

M. Kaise, J. Miwa, A. Fujimoto, et al., Influence of Helicobacter pylori status and eradication on the serum levels of trefoil factors and pepsinogen test: serum trefoil factor 3 is a stable biomarker. Gastric Cancer, 2013, 16(3): 329-337.
Crossref Google Scholar
[8]

M. Kaise, J. Miwa, J. Tashiro, et al., The combination of serum trefoil factor 3 and pepsinogen testing is a valid non-endoscopic biomarker for predicting the presence of gastric cancer: a new marker for gastric cancer risk. J Gastroenterol, 2011, 46(6): 736-745.
Crossref Google Scholar
[9]

S. Kikuchi, Y. Abe, K. Iijima, K. et al., Association between infections with CagA-positive or -negative strains of Helicobacter pylori and risk for gastric cancer in young adults. Research Group on Prevention of Gastric Carcinoma Among Young Adults. Am J Gastroenterol, 1999, 94(12): 3455-3459.
Crossref Google Scholar
[10]

K. Miki, Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels - "ABC method". Proc Jpn Acad Ser B Phys Biol Sci, 2011, 87(7): 405-414.
Crossref Google Scholar
[11]

S. Shiota, O. Matsunari, M. Watada, et al., Serum Helicobacter pylori CagA antibody as a biomarker for gastric cancer in east-Asian countries. Future Microbiol, 2010, 5(12): 1885-1893.
Crossref Google Scholar
[12]

J. Parsonnet, G.D. Friedman, N. Orentreich, et al., Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut, 1997, 40(3): 297-301.
Crossref Google Scholar
[13]

K. Sugiu, T. Kamada, M. Ito, et al., Anti-parietal cell antibody and serum pepsinogen assessment in screening for gastric carcinoma. Dig Liver Dis, 2006, 38(5): 303-307.
Crossref Google Scholar
[14]

G.I. Hwang, H.Y. Chang, H.S. Byung, et al., Predictive value of preoperative serum CEA, CA19-9 and CA125 levels for peritoneal metastasis in patients with gastric carcinoma. Cancer Res Treat, 2004, 36(3): 178-181.
Crossref Google Scholar
[15]

J. Schneider, G. Schulze, Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res, 2003, 23(6D): 5089-5093.
Google Scholar
[16]

H.J. Lin, Y.H. Hsieh, W.L. Fang, et al., Clinical manifestations in patients with alpha-fetoprotein-producing gastric cancer. Curr Oncol, 2014, 21(3): e394-e399.
Crossref Google Scholar
[17]

X. Liu, W. Sheng, and Y. Wang, An analysis of clinicopathological features and prognosis by comparing hepatoid adenocarcinoma of the stomach with AFP-producing gastric cancer. J Surg Oncol, 2012, 106(3): 299-303.
Crossref Google Scholar
[18]

Y. Kumar, N. Tapuria, N. Kirmani, et al., Tumour M2-pyruvate kinase: a gastrointestinal cancer marker. Eur J Gastroenterol Hepatol, 2007, 19(3): 265-276.
Crossref Google Scholar
[19]

D.-C. Chan, C.-J. Chen, H.-C. Chu,, et al., Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann Surg Oncol, 2007, 14(1): 84-93.
Crossref Google Scholar
[20]

S.A. Moshkovskii, Why do cancer cells produce serum amyloid A acute-phase protein? Biochemistry (Mosc), 2012, 77(4): 339-341.
Crossref Google Scholar
[21]

F. Tas, S. Karabulut, M. Serilmez, et al., Serum levels of macrophage migration-inhibitory factor (MIF) have diagnostic, predictive and prognostic roles in epithelial ovarian cancer patients. Tumour Biol, 2014, 35(4): 3327-3331.
Crossref Google Scholar
[22]

H.H. Xia, Y. Yang, K.M. Chu, et al., Serum macrophage migration-inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer. Cancer, 2009, 115(23): 5441-5449.
Crossref Google Scholar
[23]

L.G. Capelle, A.C. de Vries, J. Haringsma, et al., Serum levels of leptin as marker for patients at high risk of gastric cancer. Helicobacter, 2009, 14(6): 596-604.
Crossref Google Scholar
[24]

C. Gao, R. Xie, C. Ren, et al., Dickkopf-1 expression is a novel prognostic marker for gastric cancer. J Biomed Biotechnol, 2012, 2012: 804592.
Crossref Google Scholar
[25]

H.S. Lee, H.E. Lee, D.J. Park, et al., Clinical significance of serum and tissue Dickkopf-1 levels in patients with gastric cancer. Clin Chim Acta, 2012, 413(21-22): 1753-1760.
Crossref Google Scholar
[26]

L. Yu, L. Wang, and S. Chen, Olfactomedin 4, a novel marker for the differentiation and progression of gastrointestinal cancers. Neoplasma, 2011, 58(1): 9-13.
Crossref Google Scholar
[27]

M.A. Kaplan, M. Kucukoner, A. Inal, et al., Relationship between serum soluble vascular adhesion protein-1 level and gastric cancer prognosis. Oncol Res Treat, 2014, 37(6): 340-344.
Crossref Google Scholar
[28]

H. Yasuda, Y. Toiyama, M. Ohi, et al., Serum soluble vascular adhesion protein-1 is a valuable prognostic marker in gastric cancer. J Surg Oncol, 2011, 103(7): 695-699.
Crossref Google Scholar
[29]

N. Harbeck, M. Schmitt, M. Vetter, et al., Prospective Biomarker Trials Chemo N0 and NNBC-3 Europe Validate the Clinical Utility of Invasion Markers uPA and PAI-1 in Node-Negative Breast Cancer. Breast Care (Basel), 2008. 3(s2): 11-15.
Crossref Google Scholar
[30]

L. Herszenyi, G. Istvan, R. Cardin, et al., Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers. European Journal of Cancer Prevention, 2008, 17(5): 438-445.
Crossref Google Scholar
[31]

M.P. Ebert, S. Kruger, M.L. Fogeron, et al., Overexpression of cathepsin B in gastric cancer identified by proteome analysis. Proteomics, 2005, 5(6): 1693-1704.
Crossref Google Scholar
[32]

T. Hirano, H. Yoshioka, Serum cathepsin B levels, urinary excretion of cathepsin B and tissue cathepsin B content in the patients with gastric cancer. Nihon Geka Hokan, 1993, 62(5): 217-221.
Google Scholar
[33]

H. Umemura, A. Togawa, K. Sogawa, et al., Identification of a high molecular weight kininogen fragment as a marker for early gastric cancer by serum proteome analysis. J Gastroenterol, 2011. 46(5): 577-585.
Crossref Google Scholar
[34]

K. Shimizu, Y. Ueda, and H. Yamagishi, Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients. Gastric Cancer, 2005, 8(4): 214-219.
Crossref Google Scholar
[35]

A. Suppiah, J. Greenman, Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer. World J Gastroenterol, 2013, 19(29): 4651-4670.
Crossref Google Scholar
[36]

T. Abe, M. Fukumoto, K. Tsuchiya, et al., Human monoclonal antibodies against cytokeratin 18 generated from patients with gastric cancer. Jpn J Cancer Res, 1989, 80(3): 271-276.
Crossref Google Scholar
[37]

C. Caulin, G.S. Salvesen, and R.G. Oshima, Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol, 1997, 138(6): 1379-1394.
Crossref Google Scholar
[38]

K. Oyama, S. Fushida, J. Kinoshita, et al., Serum cytokeratin 18 as a biomarker for gastric cancer. Clin Exp Med, 2013. 13(4): 289-295.
Crossref Google Scholar
[39]

Y. Mitani, N. Oue, S. Matsumura, et al., Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy. Oncogene, 2007, 26(30): 4383-4393.
Crossref Google Scholar
[40]

Y. Hao, Y. Yu, L. Wang, et al., IPO-38 is identified as a novel serum biomarker of gastric cancer based on clinical proteomics technology. J Proteome Res, 2008, 7(9): 3668-3677.
Crossref Google Scholar
[41]

J. Zhang, K. Zhang, X. Jiang, et al., S100A6 as a potential serum prognostic biomarker and therapeutic target in gastric cancer. Dig Dis Sci, 2014, 59(9): 2136-2144.
Crossref Google Scholar
[42]

M.P. Ebert, S. Lamer, J. Meuer, et al., Identification of the thrombin light chain a as the single best mass for differentiation of gastric cancer patients from individuals with dyspepsia by proteome analysis. J Proteome Res, 2005, 4(2): 586-590.
Crossref Google Scholar
[43]

M.P. Ebert, D. Niemeyer, S.O. Deininger, et al., Identification and confirmation of increased fibrinopeptide a serum protein levels in gastric cancer sera by magnet bead assisted MALDI-TOF mass spectrometry. J Proteome Res, 2006, 5(9): 2152-2158.
Crossref Google Scholar
[44]

A. Sagripanti, A. Carpi, M. Ferdeghini, et al., The measurement of plasma fibrinopeptide A in breast cancer patients. Rays, 1987, 12(2): 65-69, 107-109.
Google Scholar
[45]

T. Yoshinaga, T. Shigemitsu, H. Nishimata, et al., Angiopoietin-like protein 2 is a potential biomarker for gastric cancer. Mol Med Rep, 2015, 11(4): 2653-2658.
Crossref Google Scholar
[46]

Y. Toiyama, K. Tanaka, T. Kitajima, et al., Serum angiopoietin-like protein 2 as a potential biomarker for diagnosis, early recurrence and prognosis in gastric cancer patients. Carcinogenesis, 2015. 36(12): 1474-1483.
Crossref Google Scholar
[47]

T. Shimura, Y. Toiyama, K. Tanaka, et al., Angiopoietin-like Protein 2 as a Predictor of Early Recurrence in Patients After Curative Surgery for Gastric Cancer. Anticancer Res, 2015, 35(9): 4633-4639.
Google Scholar
[48]

J. Jarvisalo, M. Hakama, P. Knekt, et al., Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening. Cancer, 1993, 71(6): 1982-1988.
Crossref Google Scholar
[49]

B.L. Strom, G. Maislin, S.L. West, et al., Serum CEA and CA 19-9: potential future diagnostic or screening tests for gallbladder cancer? Int J Cancer, 1990, 45(5): 821-824.
Crossref Google Scholar
[50]

S. Alberico, M.C. Facca, R. Millo, et al., Tumoral markers (CA 125-CEA) in the screening of ovarian cancer. Eur J Gynaecol Oncol, 1988. 9(6): 485-489.
Google Scholar
[51]

Y.C. Kim, J.H. Kim, D.Y. Cheung, et al., The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test. Gut Liver, 2015, 9(5): 641-648.
Crossref Google Scholar
[52]

C. Tonus, M. Sellinger, K. Koss, et al., Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis. World J Gastroenterol, 2012, 18(30): 4004-4011.
Crossref Google Scholar
[53]

M. Abdullah, A.A. Rani, M. Simadibrata, et al., The value of fecal tumor M2 pyruvate kinase as a diagnostic tool for colorectal cancer screening. Acta Med Indones, 2012, 44(2): 94-99.
Google Scholar
[54]

W. Meng, H.H. Zhu, Z.F. Xu, et al., Serum M2-pyruvate kinase: A promising non-invasive biomarker for colorectal cancer mass screening. World J Gastrointest Oncol, 2012, 4(6): 145-151.
Crossref Google Scholar
[55]

M. Iwamuro, Y. Kawai, T. Matsumoto, et al., Serum anti-p53 antibody as a tumour marker for colorectal cancer screening. Ecancermedicalscience, 2015, 9: 560.
Crossref Google Scholar
[56]

C. Ausch, V. Buxhofer-Ausch, U. Olszewski, et al., Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients. Eur J Surg Oncol, 2009, 35(11): 1164-1168.
Crossref Google Scholar
[57]

M. Ramazan Sekeroglu, S. Aydin, H. Dulger, et al., Diagnostic value of cytokeratin-18 as a tumor marker in bladder cancer. Clin Biochem, 2002, 35(4): 327-331.
Crossref Google Scholar
[58]

F. Kitahara, K. Kobayashi, T. Sato, et al., Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut, 1999, 44(5): 693-697.
Crossref Google Scholar
[59]

M.V. Liberti, J.W. Locasale, The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci, 2016, 41(3): 211-218.
Crossref Google Scholar
[60]

A. Hirayama, K. Kami, M. Sugimoto, et al., Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res, 2009, 69(11): 4918-4925.
Crossref Google Scholar
[61]

N. Abbassi-Ghadi, S. Kumar, J. Huang, et al., Metabolomic profiling of oesophago-gastric cancer: a systematic review. Eur J Cancer, 2013, 49(17): 3625-3637.
Crossref Google Scholar
[62]

M. Meuth, The molecular basis of mutations induced by deoxyribonucleoside triphosphate pool imbalances in mammalian cells. Exp Cell Res, 1989, 181(2): 305-316.
Crossref Google Scholar
[63]

L. Chang, R. Guo, Q. Huang, et al., Chromosomal instability triggered by Rrm2b loss leads to IL-6 secretion and plasmacytic neoplasms. Cell Reports, 2013, 3(5): 1389-1397.
Crossref Google Scholar
[64]

G. Weinberg, B. Ullman, and D.W. Martin, Jr., Mutator phenotypes in mammalian cell mutants with distinct biochemical defects and abnormal deoxyribonucleoside triphosphate pools. Proceedings of the National Academy of Sciences of the United States of America, 1981, 78(4): 2447-2451.
Crossref Google Scholar
[65]

E. Rysman, K. Brusselmans, K. Scheys, et al., De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res, 2010, 70(20): 8117-8126.
Crossref Google Scholar
[66]

F.P. Kuhajda, K. Jenner, F.D. Wood, et al., Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91(14): 6379-6383.
Crossref Google Scholar
[67]

Q. Qu, F. Zeng, X. Liu, et al., Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer. Cell Death Dis, 2016, 7: e2226.
Crossref Google Scholar
[68]

L. Yu, J. Aa, J. Xu, et al., Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol, 2011, 26(8): 1290-1297.
Crossref Google Scholar
[69]

S. Kumar, J. Huang, J.R. Cushnir, et al., Selected ion flow tube-MS analysis of headspace vapor from gastric content for the diagnosis of gastro-esophageal cancer. Anal Chem, 2012, 84(21): 9550-9557.
Crossref Google Scholar
[70]

C. Jin, W. Shi, F. Wang, et al., Long non-coding RNA HULC as a novel serum biomarker for diagnosis and prognosis prediction of gastric cancer. Oncotarget, 2016.
Crossref Google Scholar
[71]

Y. Zhao, Q. Guo, J. Chen, et al., Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: a clinical and in vitro investigation. Oncol Rep, 2014, 31(1): 358-364.
Crossref Google Scholar
[72]

J.S. Chen, Y.F. Wang, X.Q. Zhang, et al., H19 serves as a diagnostic biomarker and up-regulation of H19 expression contributes to poor prognosis in patients with gastric cancer. Neoplasma, 2016, 63(2): 223-230.
Crossref Google Scholar
[73]

X. Zhou, C. Yin, Y. Dang, et al., Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer. Sci Rep, 2015, 5: 11516.
Crossref Google Scholar
[74]

H. Li, B. Yu, J. Li, et al., Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget, 2014, 5(8): 2318-2329.
Crossref Google Scholar
[75]

E.B. Zhang, L. Han, D.D. Yin, et al., c-Myc-induced, long, noncoding H19 affects cell proliferation and predicts a poor prognosis in patients with gastric cancer. Med Oncol, 2014, 31(5): 914.
Crossref Google Scholar
[76]

H. Liu, L. Zhu, B. Liu, et al., Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett, 2012, 316(2): 196-203.
Crossref Google Scholar
[77]

J. Song, Z. Bai, J. Zhang, et al., Serum microRNA-21 levels are related to tumor size in gastric cancer patients but cannot predict prognosis. Oncol Lett, 2013, 6(6): 1733-1737.
Crossref Google Scholar
[78]

Y.H. Shen, Z.B. Xie, A.M. Yue, et al., Expression level of microRNA-195 in the serum of patients with gastric cancer and its relationship with the clinicopathological staging of the cancer. Eur Rev Med Pharmacol Sci, 2016, 20(7): 1283-1287.
Google Scholar
[79]

C.G. Hou, X.Y. Luo, and G. Li, Diagnostic and Prognostic Value of Serum MicroRNA-206 in Patients with Gastric Cancer. Cell Physiol Biochem, 2016, 39(4): 1512-1520.
Crossref Google Scholar
[80]

J. Zhang, Y. Song, C. Zhang, et al., Circulating MiR-16-5p and MiR-19b-3p as Two Novel Potential Biomarkers to Indicate Progression of Gastric Cancer. Theranostics, 2015, 5(7): 733-745.
Crossref Google Scholar
[81]

V.Y. Shin, E.K. Ng, V.W. Chan, et al., A three-miRNA signature as promising non-invasive diagnostic marker for gastric cancer. Mol Cancer, 2015, 14: 202.
Crossref Google Scholar
[82]

J. Song, Z. Bai, W. Han, et al., Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci, 2012, 57(4): 897-904.
Crossref Google Scholar
[83]

S. Kumar, J. Huang, N. Abbassi-Ghadi, et al., Selected ion flow tube mass spectrometry analysis of exhaled breath for volatile organic compound profiling of esophago-gastric cancer. Anal Chem, 2013, 85(12): 6121-6128.
Crossref Google Scholar
[84]

H. Amal, M. Leja, K. Funka, et al., Detection of precancerous gastric lesions and gastric cancer through exhaled breath. Gut, 2016. 65(3): 400-407.
Crossref Google Scholar
[85]

Z.Q. Xu, Y.Y. Broza, R. Ionsecu, et al., A nanomaterial-based breath test for distinguishing gastric cancer from benign gastric conditions. Br J Cancer, 2013, 108(4): 941-950.
Crossref Google Scholar
[86]

Y. Chen, Y. Zhang, F. Pan, et al., Breath Analysis Based on Surface-Enhanced Raman Scattering Sensors Distinguishes Early and Advanced Gastric Cancer Patients from Healthy Persons. ACS Nano, 2016.
Crossref Google Scholar
Nano Biomedicine and Engineering
Volume 8 Issue 4,
December 2016
Pages 268-273
DOI: 10.5101/nbe.v8i4.p268-273
Cite this article:
Fu H. New Developments of Gastric Cancer Biomarker Research. Nano Biomedicine and Engineering, 2016, 8(4): 268-273. https://doi.org/10.5101/nbe.v8i4.p268-273

419

Views

15

Downloads

4

Crossref

6

Scopus

Altmetrics
Received: 27 September 2016
Accepted: 18 November 2016
Published: 06 December 2016
© 2016 Hualin Fu.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Return